The “Health Care Consolidation and Contracting Fairness Act of 2022,” was approved by the California Assembly in May and if passed by the senate and signed into law before the Aug. 31 recess, will significantly affect healthcare M&A activity in California for a broad spectrum of healthcare providers, payors and other stakeholders, writes THe National Law Review.
The bill imposes a new formidable regulatory hurdle for deals by requiring the Attorney General to approve, deny, or conditionally approve all transactions involving for-profit medical groups, health systems, pharmacy benefit managers, health plans, health insurers and hospitals, where the value of such transaction exceeds $15 million. Read more.
